

## Disclosures

### Personal Commercial (23)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b><i>Self</i></b>			
Amgen	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
AstraZeneca Pharmaceuticals	Research/Research Grants	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Bristol-Myers Squibb	Research/Research Grants	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Congenital Heart Disease and Pediatric Cardiology</a>
CSL Vifor	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Cytokinetics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Lexicon	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Mineralfy	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Pfizer	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
PharmaN	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Roche Diagnostics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Sanofi	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Arrhythmias and Clinical EP</a>
scPharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Sumitomo	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Tricog Health	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Urovant Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Additional Personal Commercial Disclosures for Education Activities (3)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b><i>Self</i></b>			
Corcept Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Otsuka Pharmaceutical Co.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

## Expert Witness Testimony (0)

## Agreement

### **Certified Education Attestation** | Signed on 1/11/2026

*URL for full agreement:* <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### **Confidentiality, Disclosure and Assignment Agreement** | Signed on 1/11/2026

*URL for full agreement:* <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### **Embargo** | Signed on 1/11/2026

*URL for full agreement:* <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### **On-Going Obligation Agreement** | Signed on 1/11/2026

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.